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Both apixaban and rivaroxaban have been approved for use in acute venous
thromboembolism (VTE). Although indirect comparison through network meta-analyses of
randomized trials have been performed to compare the eﬃcacy and safety of these agents,
further comparison between these agents was lacking until recently. We sought to
systematically review and carry out a meta-analysis of studies to further compare apixaban
with rivaroxaban from multiple studies done in the real-world settings. Studies comparing
rivaroxaban with apixaban in patients with acute VTE were identiﬁed through electronic
literature searches of MEDLINE, EMBASE, Scopus, and the Cochrane library up to May 2019.
Study-speciﬁc risk ratios (RRs) were calculated and combined using a random-effects model
meta-analysis. In an analysis involving 24 041 patients, recurrent VTE within 6 months
occurred in 56 of 4897 patients (1.14%) in the apixaban group and 258 of 19 144 patients
(1.35%) in the rivaroxaban group (RR, 0.89; 95% conﬁdence interval [CI], 0.67-1.19; P 5 .45).
Clinically relevant major bleeding occurred in 85 of 11 559 patients (0.74%) in the apixaban
group and 350 of 33 909 patients (1.03%) in the rivaroxaban group (RR, 0.73; 95% CI, 0.580.93; P 5 .01). Clinically relevant nonmajor bleeding occurred in 169 of 3417 patients (4.95%)
in the apixaban group and 1094 of 12 475 patients (8.77%) in the rivaroxaban group (RR,
0.59; 95% CI, 0.50-0.70; P , .01). Apixaban shows equivalent eﬃcacy in prevention of
recurrent VTE but decreased risk of major and minor bleeding events compared with
rivaroxaban.

Background
Direct-acting oral anticoagulants (DOACs) such as dabigatran, apixaban, rivaroxaban, and edoxaban
are becoming the preferred agents for use in acute venous thromboembolism (VTE; deep vein
thrombosis and pulmonary embolism) compared with vitamin K antagonists (VKAs).1 Although
dabigatran and edoxaban require the sequence of unfractionated heparin or low-molecular-weight
heparin (LMWH) “lead-in” anticoagulation followed by the respective oral agent, dabigatran or
edoxaban (also referred to by some as bridging), lead-in anticoagulation is not needed when using
apixaban and rivaroxaban. Lead-in anticoagulation with heparin products adds complexity to the
treatment regimen and is 1 reason why dabigatran or edoxaban is less often prescribed than
apixaban and rivaroxaban.2 Hence, apixaban and rivaroxaban are now increasingly used for acute
VTE compared with VKAs and other DOACs.3
Although DOAC use in VTE has been shown to be noninferior to VKAs in noninferiority randomized trials,
it is unclear whether any 1 DOAC is superior to the other given lack of head-to-head comparison studies.
Network meta-analysis is done to establish indirect treatment comparison, with multiple treatments
Submitted 10 June 2019; accepted 10 July 2019. DOI 10.1182/
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being compared at the same time to the common comparator
(LMWH/warfarin in this case). Network meta-analyses in nonvalvular atrial fibrillation have provided some indirect evidence of
comparisons, but have yielded mixed results, with some studies
favoring apixaban more than rivaroxaban in different circumstances.
Apixaban has been reported to be associated with less gastrointestinal bleeding, more favored in patients with chronic kidney
disease (CKD) and overall less major bleeding (including those
patients with cancer), and a lower rate of total discontinuation.4-6
Results from a randomized controlled trial comparing apixaban and
rivaroxaban head to head (COBRRA: NCT03266783) evaluating
the relative risk of efficacy between the 2 agents and relative risk
of bleeding is pending.7 Various retrospective studies (database,
registries) have been carried out looking at head-to-head comparisons between apixaban and rivaroxaban on VTE recurrence risk
and bleeding risk.8-11 Although randomized clinical trials are
considered to be gold standard for evaluating safety and efficacy
of these agents, the population recruited for these trials may not be
generalizable. Hence, evidence generated from real-world databases and registry data can help clinicians guide selection between
these agents in day-to-day practice.12
We sought to systematically assess the available evidence on the
effectiveness and safety of apixaban compared with rivaroxaban in
terms of recurrent VTE and bleeding risks in the real world settings.

Methods
The Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) statement for reporting systematic reviews as
recommended by the Cochrane Collaboration was used for this
systematic review.13 This qualitative systematic review included
studies published from database inception up to May 2019.
Searches of MEDLINE, Cochrane Library, and EMBASE were
carried out to identify eligible studies. Comprehensive searches for
conference abstracts were also carried out. These databases were
searched using the search terms under 2 broad search themes and
combined using the Boolean operator “AND.” For the theme
“rivaroxaban,” we used a combination of medical subject headings
(MeSH), entry terms, and text words “rivaroxaban” and “factor Xa
inhibitor.” For the theme “apixaban,” we used a combination of
MeSH, entry terms, and text words “apixaban” and “factor Xa
inhibitor.” For the theme “acute venous thromboembolism,”
synonyms for “venous thromboembolism,” “deep vein thrombosis,”
and “pulmonary embolism” were used. Study designs including
case controls, observational studies, randomized controlled trials,
and meta-analyses of clinical trials were reviewed. No language
restriction was used. Bibliographies belonging to included articles,
known reviews, and relevant articles were hand-searched to identify
additional trials. To minimize data duplication as a result of multiple
reporting, we compared articles from the same investigator. Two
investigators (R.G. and A.K.) screened and retrieved reports and
excluded irrelevant studies. Relevant data were extracted by 2
investigators (R.G. and Y.B.) and checked by another (A.K.). An
additional investigator (M.R.A.) participated in the review process
when uncertainty about eligibility criteria arose.
From each study, we extracted and tabulated details on study
source type, design, patients with acute VTE, mean age in years,
percentage of female patients, estimated recurrent VTE risk,
estimated bleeding risk (major and nonmajor), VTE events, and
duration of anticoagulation; different outcomes at different time
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points were also recorded (Table 1). End points across the studies
were also listed. After reviewing all of the literature, selected studies
included all observational studies that compared the use of
apixaban with rivaroxaban. The steps of the literature search
process are summarized in Figure 1. Published full-text articles were
included for this study. The eligibility criteria for this systematic
review were: (1) human subjects with a diagnosis of acute VTE; (2)
reported outcomes comparing rivaroxaban with apixaban; (3)
minimum reported data of VTE or acute bleeding up to 3 months
of time. Studies comparing apixaban vs rivaroxaban but indicated
for the use of atrial fibrillation (AF) were not included in our review as
these looked at stroke outcomes and outcomes were heterogeneous. In addition, studies that compared use of rivaroxaban or
apixaban to warfarin or LMWH were excluded as these studies did
not have direct comparison of apixaban with rivaroxaban. Finally,
studies not reporting VTE and bleeding outcomes were also
excluded from our analysis. In studies that had inclusion of both AF
and VTE patients, data were extracted for patients with VTE only.11
The study by Lutsey et al was included only for major bleeding
outcome because the VTE events and minor bleeding events were
not recorded.14 A total of 5 studies were included for analysis: 1
study included a review of data from a thrombophilia clinic registry,
1 study included a review of retrospective data of veterans, and 3
were database studies from the United States and Denmark.8-11,14
Study quality was formally evaluated by 2 investigators using
a modified Newcastle-Ottawa Quality Assessment Scale for
retrospective studies (supplemental Table 2).
One efficacy outcome (VTE recurrence up to 6 months) and 2
safety outcomes (major and minor bleeding) were assessed.
Efficacy was defined as recurrence of VTE (composite of any
recurrent deep vein thrombosis or pulmonary embolism) reported
as positive imaging findings on ultrasound Doppler or computed
tomography. For our safety outcomes, clinically relevant major
bleeding was reported (composite of bleeding requiring intervention
or transfusion, cardiac tamponade, or pericardial effusion
requiring drainage, retroperitoneal bleeding, intracranial bleed,
massive hemoptysis, hemithorax, bleeding requiring extra hospital stay) and patients requiring hospitalization. Minor bleeding
was defined by gastrointestinal bleeding, puncture site bleeding,
thigh ecchymosis, hematoma, epistaxis, or bleeding with no
intervention or without transfusion. Minor bleeding was considered to be secondary end point for analysis. For our analysis,
we chose studies reporting outcomes up to 6 months. For
studies reporting outcomes both at 3 months and 6 months, for
uniformity, 3-month outcomes were chosen for analysis, as
most studies reported outcomes at the 3-month interval. For
the calculation of hazard ratio (HR), given the heterogeneous
data reporting, 2 studies (Dawwas et al10 and Lutsey et al14)
reported 3-month outcomes, and these studies were used. Thus,
all of the studies could not be combined for overall major bleeding
events based on HR. Outcomes from the individual studies were
calculated with RevMan version 5.3 (Cochrane Collaboration,
Oxford, United Kingdom). A formal systematic review was
performed applying the Mantel-Haenszel test using the software.
Risk ratios (RRs) and 95% confidence intervals (CIs) were
estimated using a random-effects method to control the heterogeneity, as their assumption accounts for the presence of variability
among the studies. HR was calculated using the same software.
When provided, we used the CI and HRs from the included studies
13 AUGUST 2019 x VOLUME 3, NUMBER 15

Table 1. Baseline characteristics of included studies
Sindet-Pedersen et al,8
2018

Lutsey et al,14 2019

Bott-Kitslaar,9 2018

Dawwas et al,10 2019

Howe et al,11 2018

Source type

Journal article

Journal article

Journal article

Journal article

Journal article

Study design

Retrospective, multicenter
registry

Retrospective, market scan
data warehouse

Prospective, single-center trial
(Mayo Thrombophilia Clinic
Registry), observational

Retrospective cohort analysis,
market scan and Medicare
supplement claims 20142016

Retrospective review,
single VA center

Mean age, y

Female sex, %

Mean weight, kg

70 A*

60.4 A

62.4 A

61.5 A

73 A

67 R*

56.4 R

58.5 R

56.5 R

68 R

50.8 A

50.3 A

38.7 A

50.6 A

2A

45.3 R

49.2 R

48 R

49.5 R

4.4 R

NS

NS

87.6 A

NS

NS

NS

91.3 R
Medications, %
Antiplatelet agents

23.6 A

7A

23.8 A

7.3 A

18.3 R

5.1 R

21.8 R

4.2 R

14 A

17 A

47 A

17.7 A

Malignancy

11.4 R

16.1 R

39.9 R

18.9 R

Chronic kidney

3.9 A

13.2 A

2.3 A†

17.1 A

Comorbidities, %

2.7 R
Total duration of study, mo

29

Study groups (total no. of
patients in each group)

2 groups
A (1504)
R (6683)

Primary outcome

All-cause mortality, recurrent
VTE, hospitalized bleeding

Secondary outcome

Intracranial and
gastrointestinal bleeding

Recurrent VTE, %

1.71 A

7.1 R

Nonmajor/minor bleeding, %

0R

NS

8.5 R

58

24

24

2 groups

2 groups

2 groups

2 groups

A (6786)

A (302)

A (3091)

A (89)

R (30 982)
Hospitalized bleeding

NS

1.76 R
Major bleeding, %

†

NS

R (298)

R (12 163)

VTE recurrence, major
bleeding events

R (173)

VTE recurrence, major
bleeding events

Overall bleeding rates

CRNMB, and composite of
Minor bleeding events
major bleeding and CRNMB

Time to bleeding and
location of bleeding

2.32 A

0.81 A

2.01 R

2.09 R

NS

1.17 A

0.74 A

3.64 A

0.91 A

0.56 A

1.28 R

1.15 R

3.20 R

1.55 R

1.99 R

NS

NS

2.32 A

5.37 A

0.28

6.71 R
Study outcomes reported at

Average 6 mo

3 mo and 6 mo

Major outcomes reported as

Incidence reported as percent Adjusted HR for 100 personevents, ARR between 2
year incidence, number of
groups
events at 3 mo

8.90 R

3 mo and overall as 100
per year incidence

,3 mo and .3 mo and
100 person-year

1.77 R
At 3 mo and 100 personyear

No. of events at ,3 mo and
No. of events at 3 mo and
.3 mo, HR for the same and
100 person-year
also for 100 person-year
incidence
incidence

A, apixaban; ARR, absolute risk reduction; CRNMB, clinically relevant nonmajor bleeding; NS, not specified; R, rivaroxaban; VA, Veterans Affairs; W, warfarin.
*Median.
†
Creatinine clearance ,30 mL/min.

at the 3-month interval. The I2 statistic was used to assess
heterogeneity among the studies. P value was computed and was
considered significant if ,.05, and CIs were calculated.

Results
Although the 5 selected studies8-11,14 assessed similar efficacy end
points and outcomes, they were slightly different in terms of overall
design and outcome definitions (Table 1).
There were a total of 45 468 patients analyzed for the primary
efficacy of recurrent VTE and the safety outcomes of major bleeding
and minor bleeding events. One study had combined patients with
13 AUGUST 2019 x VOLUME 3, NUMBER 15

both AF and VTE, however, we included only those evaluated for
VTE.11
In 3 studies involving 24 041 patients, recurrent VTE up to 6 months
occurred in 56 of 4897 patients (1.14%) in the apixaban group and
258 of 19 144 patients (1.35%) in the rivaroxaban group (RR, 0.89;
95% CI, 0.67-1.19; P 5 .45; I2 5 0%) (Figure 2). Clinically relevant
major bleeding occurred in 85 of 11 559 patients (0.74%) in the
apixaban group and 350 of 33 909 patients (1.03%) in the
rivaroxaban group (RR, 0.73; 95% CI, 0.58-0.93; P 5 .01; I2 5
0%) (Figure 3). Sensitivity analysis for major bleeding was carried
out, excluding the study by Howe et al11 because it contributed the
APIXABAN AND RIVAROXABAN FOR VTE TREATMENT
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study selection process.

EMBASE
(n = 545)

Cochrane Library
(n = 31)

Screening

MEDLINE
(n = 631)

Studies after duplicates removed
(n = 549)

Eligibility

Identification

Figure 1. Flow chart describing systematic research search and

Articles assessed for
eligibility (n = 549)

Did not meet
Inclusion criteria
(n = 544)

Included

Hand Search (n = 0)

Studies included in
quantitative synthesis
(n = 5)

least number of patients to the analysis (supplemental Figure 1).
Further sensitivity analysis was also carried out excluding SindetPedersen et al,8 as the major bleeding outcomes were reported at
mean of 6 months, compared with others, which reported outcomes
at 3 months (supplemental Figure 2). Both of these sensitivity
analyses did not change the reported outcome of major bleeding
favoring apixaban. Clinically relevant nonmajor bleeding occurred in
169 of 3417 patients (4.95%) in the apixaban group and 1094 of
12 475 patients (8.77%) in the rivaroxaban group (RR, 0.59; 95%
CI, 0.50-0.70; P , .01; I2 5 0%) (Figure 4).
Furthermore, analysis was carried out for clinically relevant
composite outcomes of major and minor bleeding, and composite
outcomes of VTE and major bleeding. The composite outcomes of
major and minor bleeding occurred in 190 of 3417 patients (5.56%)
in the apixaban group and 1186 of 12 475 patients (9.51%) in the

Apixaban
Study or Subgroup
Bott-Kitslaar 2018

Events Total
3

Total

2

An outcome table summarizing the results is also provided
(supplemental Table 1). Outcomes of intracranial hemorrhage,
gastrointestinal bleeding or cardiac bleeding, and mortality could
not be looked at separately as they were inconsistently reported.
Also, the comparison between apixaban and rivaroxaban, for
treatment in cancer and CKD patients, could not be made, as

Risk Ratio

Risk Ratio
Weight

M-H, Random, 95% CI
1.48 [0.25, 8.79]

298

2.6%

Dawwas 2019

20 3091

108 12163

37.1%

0.73 [0.45, 1.17]

Sindet-Pedersen 2018

33 1504

148

6683

60.3%

0.99 [0.68, 1.44]

19144

100.0%

0.89 [0.67, 1.19]

4897

Total (95% CI)
Total events

302

Rivaroxaban
Events

rivaroxaban group (RR, 0.60; 95% CI, 0.52-0.70; P , .01; I2 5 0%)
(supplemental Figure 3).The composite outcomes of VTE and major
bleeding occurred in 102 of 4897 patients (2.08%) in the apixaban
group and 483 of 19 144 (2.52%) in the rivaroxaban group (RR,
0.79; 95% CI, 0.58-1.06; P 5 .12; I2 5 38%) (supplemental
Figure 4). Major bleeding was also calculated utilizing HR at 3
months. The risk of major bleeding at 3 months used HR, including
the Dawwas et al10 and Lutsey et al14 studies (HR, 0.56; 95% CI,
0.43-0.72; P , .01; I2 5 0%) (supplemental Figure 5).

56

M-H, Random, 95% CI

258

Heterogeneity: Tau2 = 0.00; Chi2= 1.31, df = 2 (P = 0.52); I2 = 0%
Test for overall effect: Z = 0.76 (P = 0.45)

0.01

0.1

Favours [apixaban]

1

10

Favours [rivaroxaban]

Figure 2. VTE events.
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Apixaban
Study or Subgroup

Events Total

Bott-Kitslaar 2018
Dawwas 2019

6

Total

Weight

M-H, Random, 95% CI

6

298

4.5%

0.99 [ 0.32, 3.02]

84 12163

302

14 3091
1

Howe 2018

Risk Ratio

Risk Ratio

Rivaroxaban
Events

24

2

17.9%

0.66 [ 0.37, 1.15]

14

1.1%

0.29 [ 0.03, 2.93]

Lutsey 2019

38 6638

132 14751

44.0%

0.64 [ 0.45, 0.92]

Sindet-Pedersen 2018

26 1504

126

6683

32.5%

0.92 [ 0.60, 1.39]

33909

100.0%

0.73 [0.58, 0.93]

Total (95% CI)
Total events

11559
85

M-H, Random, 95% CI

350

Heterogeneity: Tau2 = 0.00; Chi2= 2.68, df = 4 (P = 0.61); I2 = 0%
Test for overall effect: Z = 2.58 (P = 0.010)

0.01

0.1

1

Favours [apixaban]

10

100

Favours [rivaroxaban]

Figure 3. Major bleeding events.

This meta-analysis directly compared apixaban to rivaroxaban in
patients with acute VTE, and identified no difference in VTE
recurrence and composite outcome of recurrent VTE and major
bleeding between apixaban and rivaroxaban. However, both major
bleeding and minor bleeding events were significantly higher in the
rivaroxaban group. Our results are consistent with a prior network
meta-analysis that indirectly compared these agents.4 Previous
studies have shown apixaban to be safer in patients with advanced
age, baseline active cancer, CKD, and provoked VTE. It is
interesting to note that the overall incidence of VTE was very low
in both groups, which had been reported in prior randomized
controlled trials (RCTs) but had not been confirmed in real-world
patients with less adherence compared with randomized trial
participants.15,16

a dreaded complication with any factor Xa inhibitors. Although
a reversal agent, andexanet, has been recently approved for
apixaban and rivaroxaban, it has several limitations in terms of short
half-life, potential increased risk of thrombosis, absence of RCTs on
its efficacy, and cost.17 Hence, complications are often managed
conservatively. Our study provides further evidence that apixaban
might be a better choice for anticoagulation than rivaroxaban in
terms of bleeding risk pending the ongoing RCT previously
mentioned.7 At the very least, our results would appear to favor
the use of apixaban in patients with a preexisting increased risk to
bleed, for example, those with CKD, heavy menses, or history of
gastrointestinal bleed. In these circumstances, our findings suggest
that patients who are taking long-term rivaroxaban will likely benefit if
switched to apixaban if they are able to adhere to twice-daily
treatment. However, it should be noted that our findings are
applicable to VTE patients (not AF) only, and whether this study’s
findings would continue to hold true beyond 6 months follow-up is
unclear. Although decreased bleeding with apixaban exists, it may
be small as evidenced by number needed to harm, which can be
useful information while discussing the options of anticoagulation
between these agents with our patients.

Bleeding complications are an important consideration when
choosing any systemic anticoagulation. Major bleeding, such as
central nervous system bleeding and cardiac tamponade, can be

Although confounders are possible in retrospective studies (eg,
weight not being consistently addressed), they appear to have been
well matched and propensity scoring was carried out in these

these are not available in all studies. On further analysis, of the
number needed to harm using relative risk, we found that on
average, 345 patients would have to receive apixaban (instead of
rivaroxaban) for 1 additional patient to not have the study outcome
of major bleeding (number needed to harm).

Discussion

Apixaban
Study or Subgroup
Bott-Kitslaar 2018
Dawwas 2019
Howe 2018

Events Total
3

0

Total (95% CI)
Total events

302

166 3091
24

Weight

M-H, Random, 95% CI

Total

11

298

1.7%

0.27 [0.08, 0.95]

1082 12163

98.0%

0.60 [0.52, 0.71]

14

0.3%

0.20 [0.01, 4.60]

12475

100.0%

0.59 [0.50, 0.70]

1

3417
169

Risk Ratio

Risk Ratio

Rivaroxaban
Events

M-H, Random, 95% CI

1094

Heterogeneity: Tau2 = 0.00; Chi2= 2.00, df = 2 (P = 0.37); I2 = 0%
Test for overall effect: Z = 6.16 (P  0.00001)

0.01

0.1

Favours [apixaban]

1

10

100

Favours [rivaroxaban]

Figure 4. Clinically relevant nonmajor bleeding.
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studies. Furthermore, the coding for bleeding was not identical in all
studies, varying from International Classification of Diseases (ICD)
codes10 to International Society on Thrombosis and Haemostasis
(ISTH) bleeding definition.9 A previous meta-analysis had shown
that in various settings, including in CKD patients, apixaban was
safer than other agents like rivaroxaban and dabigatran.18 Safety
of apixaban compared with rivaroxaban has been explained in
relation to pharmacokinetic properties. Persistence of anticoagulation effects beyond the half-life of rivaroxaban allows for once-daily
dosing whereas apixaban is dosed twice daily. For this to happen,
rivaroxaban concentrations must remain higher than the minimum
concentration necessary to prevent thrombosis with the short halflife, hence the maximum serum concentration is needed to facilitate
once-daily dosing. Peak-to-trough ratio of rivaroxaban is ;10 (at
a dose of 10-20 mg once daily) whereas for apixaban is ;3 (at
a dose of 5 mg twice daily). Hence, the more favorable bleeding
profile is proposed to be a result of the decreased peak-to-trough
ratios afforded by twice-daily DOAC dosing.19

Strengths and limitations
This meta-analysis compared apixaban “directly” short of head-tohead RCT to rivaroxaban and included a large patient sample that
was representative of real-world data rather than clinical trial events.
I2 (heterogeneity) of the studies is low in most of the outcomes,
pointing toward consistent results of our analyzed outcomes. At the
same time, the presence of unaccountable confounders must be
considered when interpreting our results, especially in light of the
nonrandomized designs, despite various analyses performed in the
included studies to reduce the confounders.20 Underdosing has
been reported with DOACs, with some studies suggesting that it
might be more prevalent with apixaban (24%) than rivaroxaban
(13%), which could be associated with increased VTE events
and fewer bleeding complications.21 Given that this was based on

database and registry data, it is impossible to know the doses and
compliance of each agent used. Relatively uniform reporting of the
events within 6 months allowed us to combine these studies. It
should also be noted that major outcomes such as intracranial
bleeding, gastrointestinal bleeding, and mortality were inconsistently reported with the studies included. This was also true for
other minor outcomes.

Conclusion
In conclusion, this real-world meta-analysis comparing apixaban to
rivaroxaban suggests similar efficacy but better safety for patients
on apixaban.
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